- In December 2024, Cipla has received regulatory approval from the CDSCO to exclusively distribute and market Afrezza (insulin human) Inhalation Powder in India. This approval will enhance Cipla's diabetes portfolio and expand its presence in the rapidly growing diabetes care market in India
- In August 2024, Abbott has partnered with Medtronic to develop an integrated continuous glucose monitoring (CGM) system using Abbott's FreeStyle Libre technology, which will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. This collaboration will enable automatic insulin adjustments to maintain glucose levels, with the CGM sensor developed by Abbott and sold by Medtronic. This partnership will enhance both companies' product offerings and expand their market reach in diabetes management
- In July 2024, Amylyx Pharmaceuticals has acquired avexitide from Eiger BioPharmaceuticals, a drug previously studied for treating hyperinsulinemic hypoglycemia. This acquisition will strengthen Amylyx's pipeline and expand its focus on innovative therapies for metabolic disorders
- In May 2024, Arecor Therapeutics has partnered with Medtronic to develop a novel, high-concentration, thermostable insulin for Medtronic's next-generation implantable pump. This collaboration will enable both companies to enhance their diabetes treatment offerings and strengthen their positions in the growing insulin delivery market
- In June 2020, the FDA has approved Eli Lilly's Lyumjev (insulin lispro-aabc injection) for improving glycemic control in adults with type 1 and type 2 diabetes. This approval will strengthen Lilly's position in the rapid-acting insulin market and expand its product portfolio in diabetes care
